269 related articles for article (PubMed ID: 34323445)
1. Pancreatic Cancer Related Pain: Review of Pathophysiology and Intrathecal Drug Delivery Systems for Pain Management.
Carvajal G
Pain Physician; 2021 Aug; 24(5):E583-E594. PubMed ID: 34323445
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment.
Ontario Health
Ont Health Technol Assess Ser; 2024; 24(2):1-162. PubMed ID: 38344326
[TBL] [Abstract][Full Text] [Related]
4. Rationale and Recent Advances in Targeted Drug Delivery for Cancer Pain: Is It Time to Change the Paradigm?
Dupoiron D; Duarte R; Carvajal G; Aubrun F; Eldabe S
Pain Physician; 2022 May; 25(3):E414-E425. PubMed ID: 35652767
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study.
Zheng S; He L; Yang X; Li X; Yang Z
Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US.
Goel V; Kumar V; Blaes A; Gulati A
Neuromodulation; 2023 Aug; 26(6):1256-1262. PubMed ID: 37318432
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis.
Duarte R; Copley S; Nevitt S; Maden M; Al-Ali AM; Dupoiron D; Eldabe S
Neuromodulation; 2023 Aug; 26(6):1126-1141. PubMed ID: 35422368
[TBL] [Abstract][Full Text] [Related]
8. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal Drug Delivery for Chronic Pain Syndromes: A Review of Considerations in Practice Management.
Abd-Elsayed A; Karri J; Michael A; Bryce D; Sun J; Lee M; Orhurhu V; Deer T
Pain Physician; 2020 Nov; 23(6):E591-E617. PubMed ID: 33185379
[TBL] [Abstract][Full Text] [Related]
10. Attitudes of Hospice Providers Regarding Intrathecal Targeted Drug Delivery for Patients With Cancer.
Warner LL; Moeschler SS; Pittelkow TP; Strand JJ
Am J Hosp Palliat Care; 2019 Nov; 36(11):955-958. PubMed ID: 31132860
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry.
Stearns LM; Abd-Elsayed A; Perruchoud C; Spencer R; Hammond K; Stromberg K; Weaver T
Anesth Analg; 2020 Feb; 130(2):289-297. PubMed ID: 31567325
[TBL] [Abstract][Full Text] [Related]
12. Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer.
Sindt JE; Odell DW; Dalley AP; Brogan SE
Neuromodulation; 2020 Oct; 23(7):978-983. PubMed ID: 32459393
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Initial Intrathecal Drug Ratio for Refractory Cancer-Related Pain for Early Pain Relief. A Retrospective Monocentric Study.
Dupoiron D; Leblanc D; Demelliez-Merceron S; Bore F; Seegers V; Dubois PY; Pechard M; Robard S; Delorme T; Jubier-Hamon S; Carvajal G; Lebrec N
Pain Med; 2019 Oct; 20(10):2033-2042. PubMed ID: 31329956
[TBL] [Abstract][Full Text] [Related]
14. The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia.
Sindt JE; Larsen SD; Dalley AP; Collier WH; Brogan SE
Anesth Analg; 2020 Jul; 131(1):280-287. PubMed ID: 31990731
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal Drug Delivery for the Treatment of Cancer-Associated Chronic Pain in Children.
Kenfield M; Zacharias N; Abd-Elsayed A
Neuromodulation; 2023 Aug; 26(6):1153-1163. PubMed ID: 34520605
[TBL] [Abstract][Full Text] [Related]
16. Updated Review and Treatment Recommendations on Paraneoplastic Neurologic Syndromes and Chronic Pain.
Blyakhman I; Chakravarthy K
Pain Physician; 2019 Sep; 22(5):433-445. PubMed ID: 31561645
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates.
Upadhyay SP; Mallick PN
Am J Hosp Palliat Care; 2012 Aug; 29(5):388-98. PubMed ID: 22089523
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal therapy for cancer and non-cancer pain.
Hayek SM; Deer TR; Pope JE; Panchal SJ; Patel VB
Pain Physician; 2011; 14(3):219-48. PubMed ID: 21587327
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal drug delivery for pain management: recent advances and future developments.
Jain S; Malinowski M; Chopra P; Varshney V; Deer TR
Expert Opin Drug Deliv; 2019 Aug; 16(8):815-822. PubMed ID: 31305165
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
